140 related articles for article (PubMed ID: 30074275)
1. Disrupting cholesterol esterification by bitter melon suppresses triple-negative breast cancer cell growth.
Shim SH; Sur S; Steele R; Albert CJ; Huang C; Ford DA; Ray RB
Mol Carcinog; 2018 Nov; 57(11):1599-1607. PubMed ID: 30074275
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.
Sur S; Nakanishi H; Flaveny C; Ippolito JE; McHowat J; Ford DA; Ray RB
Cell Commun Signal; 2019 Oct; 17(1):131. PubMed ID: 31638999
[TBL] [Abstract][Full Text] [Related]
3. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.
Yung MM; Ross FA; Hardie DG; Leung TH; Zhan J; Ngan HY; Chan DW
Integr Cancer Ther; 2016 Sep; 15(3):376-89. PubMed ID: 26487740
[TBL] [Abstract][Full Text] [Related]
4. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification.
Antalis CJ; Uchida A; Buhman KK; Siddiqui RA
Clin Exp Metastasis; 2011 Dec; 28(8):733-41. PubMed ID: 21744083
[TBL] [Abstract][Full Text] [Related]
5. Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-α serine/threonine-protein kinase signaling.
Brennan VC; Wang CM; Yang WH
J Med Food; 2012 Apr; 15(4):325-34. PubMed ID: 22191569
[TBL] [Abstract][Full Text] [Related]
6. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.
Ray RB; Raychoudhuri A; Steele R; Nerurkar P
Cancer Res; 2010 Mar; 70(5):1925-31. PubMed ID: 20179194
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of
Kilcar AY; Yildiz O; Dogan T; Sulu E; Takan G; Muftuler FZB
Anticancer Agents Med Chem; 2020; 20(12):1497-1503. PubMed ID: 32329694
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
[TBL] [Abstract][Full Text] [Related]
9. Bitter Melon Prevents the Development of 4-NQO-Induced Oral Squamous Cell Carcinoma in an Immunocompetent Mouse Model by Modulating Immune Signaling.
Sur S; Steele R; Aurora R; Varvares M; Schwetye KE; Ray RB
Cancer Prev Res (Phila); 2018 Apr; 11(4):191-202. PubMed ID: 29061560
[TBL] [Abstract][Full Text] [Related]
10. Bitter melon protects against ER stress in LS174T colonic epithelial cells.
Kunde DA; Chong WC; Nerurkar PV; Ahuja KD; Just J; Smith JA; Guven N; Eri RD
BMC Complement Altern Med; 2017 Jan; 17(1):2. PubMed ID: 28049460
[TBL] [Abstract][Full Text] [Related]
11. ACAT1-mediated METTL3 acetylation inhibits cell migration and invasion in triple negative breast cancer.
Zhang G; Huang R; Zhao H; Xia Y; Huang H; Qian M; Fu Y; Cui Y
Genes Immun; 2023 Apr; 24(2):99-107. PubMed ID: 36890220
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
13. Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.
Bhattacharya S; Muhammad N; Steele R; Kornbluth J; Ray RB
Cancer Prev Res (Phila); 2017 Jun; 10(6):337-344. PubMed ID: 28465362
[TBL] [Abstract][Full Text] [Related]
14. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
15. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.
Torres-Adorno AM; Vitrac H; Qi Y; Tan L; Levental KR; Fan YY; Yang P; Chapkin RS; Eckhardt BL; Ueno NT
Oncogene; 2019 Mar; 38(12):2135-2150. PubMed ID: 30459358
[TBL] [Abstract][Full Text] [Related]
16. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.
Ru P; Steele R; Nerurkar PV; Phillips N; Ray RB
Cancer Prev Res (Phila); 2011 Dec; 4(12):2122-30. PubMed ID: 21911444
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
[TBL] [Abstract][Full Text] [Related]
18. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b.
Wahdan-Alaswad RS; Cochrane DR; Spoelstra NS; Howe EN; Edgerton SM; Anderson SM; Thor AD; Richer JK
Horm Cancer; 2014 Dec; 5(6):374-89. PubMed ID: 25213330
[TBL] [Abstract][Full Text] [Related]
19. Bitter Melon Extract Yields Multiple Effects on Intestinal Epithelial Cells and Likely Contributes to Anti-diabetic Functions.
Chang CI; Cheng SY; Nurlatifah AO; Sung WW; Tu JH; Lee LL; Cheng HL
Int J Med Sci; 2021; 18(8):1848-1856. PubMed ID: 33746602
[TBL] [Abstract][Full Text] [Related]
20. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
